UPDATE 5-Novartis $2 mln gene therapy for rare disorder is world's most expensive drug
May 24, 2019 at 18:48 PM EDT
Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million.